5 November 2026

Sterile Drug Manufacturing in India: Proposed WHO-Aligned Microbial Limits and Mandatory Authorisation of Personnel for Batch Release

Sterile Drug Manufacturing in India: Proposed WHO-Aligned Microbial Limits and Mandatory Authorisation of Personnel for Batch Release

On 28 October 2026, the Ministry of Health and Family Welfare issued two draft notifications proposing amendments to the Drugs Rules, 1945. The proposed amendments seek to align microbial contamination limits for sterile pharmaceutical manufacturing areas with WHO Report Standards and introduce a formal requirement for manufacturers to authorise a suitably qualified and experienced person responsible for batch release. Both notifications invite objections and suggestions from stakeholders within 30 days from the date on which copies of the relevant Gazette notifications are made available to the public.

Importance of the Proposed Amendments

Sterile pharmaceutical products, including small-volume injectables, large-volume parenterals and sterile ophthalmic preparations, require stringent controls to prevent microbial contamination. The presence of microorganisms in such products may pose risks to patient safety. The proposed amendments seek to revise the recommended microbial contamination limits under Schedule M and introduce requirements for authorisation of suitably qualified and experienced personnel for batch release along with prescribed batch-release along with prescribed batch-release documentation thereby strengthening compliance with Good Manufacturing Practices ("GMP"). The two draft notifications are:
  • G.S.R. 953(E): Draft amendment proposing revision of microbial contamination limits under Schedule M to align the limits with WHO recommendations.
  • G.S.R. 955(E): Draft amendment proposing mandatory authorisation of a suitably qualified and experiences person responsible for batch release along with prescribed batch release documentation and record-keeping requirements.

1. G.S.R. 953(E): Revision of Microbial Contamination Limits in Alignment with WHO Standards

Understanding Grades A to D

Sterile pharmaceutical products are manufactured in controlled cleanroom environments classified into Grades A, B, C and D, based on the level of environmental control required for different manufacturing operations.

  • Grade A: The critical zone for high-risk aseptic operations, where exposed products, containers and sterilised components are handled.
  • Grade B: The background environment supporting Grade A aseptic operations.
  • Grades C and D: Controlled environments used for less critical stages of sterile manufacturing.

Manufacturers monitor these environments through different sampling methods to assess microbial contamination. The results are measured in Colony-Forming Units (“CFU”), which indicate the number of viable microorganisms present in a sample.

What does the draft propose?

The Ministry proposes to substitute Table 3 under Requirement 4, Paragraph 4.9 of Part II of Schedule M, which prescribes recommended limits for microbial contamination in sterile manufacturing environments.

The proposed limits are aligned with WHO Technical Report Series No. 1044, Annexure 2, concerning GMP for sterile pharmaceutical products.

The revised limits proposed under the draft are as follows:

Grade

Air sample (CFU/m³)

Settle plates (CFU/4 hours)

Contact plates (CFU/plate)

Glove print (CFU/glove)

A

No growth

No growth

No growth

No growth

B

10

5

5

5

C

100

50

25

Not specified

D

200

100

50

Not specified

The proposed limits cover four environmental monitoring methods which includes air sampling, settle plates, contact plates and glove prints. Particular emphasis has been placed on Grade A environments, for which the draft prescribes no microbial growth across all four specified monitoring methods.

What is the significance of the proposed revision?

The proposed amendment seeks to address the discrepancy between the microbial contamination limits under Schedule M and the corresponding requirements under the WHO Report Stamdards. Under the existing Schedule M, the Grade A microbial contamination limit is expressed as less than 1 CFU across the specified monitoring methods. The proposed amendment replaces this threshold with the express requirement of "No growth" thereby aligning the Indian limits with the corresponding WHO requirements. The revision is expected to promote consistency in environmental monitoring practices and strengthen contamination control in critical sterile manufacturing environments.

Why is the amendment being proposed?

The issue was examined by the Drugs Consultative Committee (DCC), which identified discrepancies between the microbial contamination limits prescribed under Schedule M and those under the WHO Technical Report Series 1044, annexure II. The matter was subsequently considered by the Drugs Technical Advisory Board (DTAB) at its 93rd meeting in February 2026 where the proposal to align the domestic microbial contamination limits with WHO requirements was considered. The proposed harmonisation aims to bring India's regulatory requirements for sterile pharmaceutical manufacturing in line with internationally recognised GMP standards and promote greater consistency in microbial contamination control practices.

2. G.S.R. 955(E): Mandatory Authorisation of a Qualified Person for Batch Release 

Understanding Batch Release

Batch release is an important quality assurance process undertaken before a manufactured drug batch is released for distribution or supply. It involves reviewing the relevant manufacturing, packaging, environmental monitoring and quality control documentation to establish whether the batch has been manufactured and tested in accordance with applicable GMP requirements. The proposed amendment seeks to introduce a requirement for manufacturers to authorise a suitably qualified and experienced person for batch release in compliance with Schedule M. It also prescribes the documentation to be maintained for each batch including manufacturing records, packaging records, environmental monitoring records and a Certificate of Analysis as specified under the Schedule U.

What does the draft propose?

The draft proposes the following amendments to the Drugs Rules, 1945:

1. Insertion of New Rule 68C

A new Rule 68C is proposed to be inserted after Rule 68B. It provides that an applicant seeking a licence under the relevant provisions must authorise a person having appropriate qualifications and experience for batch release in compliance with Schedule M. The records relating to the release of each manufactured drug batch must also be prepared in accordance with the particulars prescribed under Schedule U.

2. Amendments to Existing Licensing Provisions

The draft also proposes consequential amendments to Rules 74, 74A, 74B, 78, 78A and 122G along with relevant provisions of Schedule F to incorporate batch release and related record-keeping requirements.

3. Introduction of a Batch Release Certificate under Schedule U

The draft proposes insertion of a new Part IV in Schedule U, prescribing the particulars to be recorded in a Batch Release Certificate. The certificate is proposed to contain the following particulars:

  • Certificate number.
  • Name and dosage form of the product.
  • Active ingredients and their quantities per unit dose.
  • Licence number and date of issue.
  • Batch/lot number and batch/lot size.
  • Manufacturing date and expiry/retest date.
  • Names and addresses of all manufacturing and testing sites.
  • Name and address of the marketer.
  • Details of qualified equipment used.
  • Environmental monitoring records.
  • Batch manufacturing and packaging records.
  • Line clearance details.
  • In-process Quality Control (IPQC) test reports.
  • Details of testing protocols applied.
  • Certificate of Analysis (CoA).
  • Results of analysis.
  • Analytical report number.

The Batch Release Certificate shall also contain a Certificate of Conformity under which the authorised person certifies that the relevant batch has been manufactured (including packaging) and tested at the specified sites in compliance with the GMP requirements under the Drugs Rules, 1945. The certificate is to be dated and signed by the authorised person.

Regulatory significance

The proposed amendment seeks to formalise accountability for batch release by requiring applicants covered under the relevant licensing provisions to authorise a suitably qualified and experienced person for this responsibility. It also introduces a prescribed documentation framework requiring specified manufacturing, packaging, environmental monitoring and quality control records to be maintained for each batch, as detailed under the proposed Part IV of Schedule U. These measures are expected to strengthen batch traceability, quality assurance and regulatory oversight of pharmaceutical manufacturing operations.

3. Timeline and Stakeholder Comments

Both draft notifications were dated 28 October 2026 and published in the Gazette of India on 29 October 2026.

  • Period for objections and suggestions: Stakeholders may submit their objections and suggestions within 30 days from the date on which copies of the Gazette notifications are made available to the public.
  • Address for submission: Objections and suggestions may be submitted to Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, U-6, Work Hall- C Wing, First Floor, Kartavya Bhawan-1, New Delhi, 110001 or emailed at [email protected].
  • Proposed commencement: The proposed requirements are not yet operative and will be subject to final notification by the Central Government. The two draft notifications prescribe different commencement provisions:

1. G.S.R. 953(E): The amendment will come into force from the date specified by the Government at the time of final publication in the Official Gazette.

2. G.S.R. 955(E): The proposed amendment will come into force three months after its publication in the Official Gazette.

Conclusion

The two proposed amendments reflect the Government's continued efforts to strengthen pharmaceutical manufacturing standards and quality assurance in India. While G.S.R. 953(E) focuses on harmonising environmental microbial monitoring requirements with WHO standards, G.S.R. 955(E) seeks to strengthen accountability in batch release through the authorisation of suitably qualified and experienced personnel and the introduction of prescribed batch documentation requirements. Pharmaceutical manufacturers should review the proposed amendments and assess their existing environmental monitoring, quality assurance, batch documentation and release procedures to identify areas that may require alignment with the proposed requirements.